<DOC>
	<DOCNO>NCT01708902</DOCNO>
	<brief_summary>Reduced factorial design study 24 week randomize treatment initial combination therapy linagliptin metformin T2DM patient</brief_summary>
	<brief_title>Study Compare Efficacy Safety Administration Fix Dose Combination Linagliptin Plus Metformin Drug naïve Type 2 Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis Type 2 diabetes mellitus ( T2DM ) prior inform consent 2 . Male female patient diet exercise regimen drugnaïve 3 . Glycosylated haemoglobin A1c ( HbA1c ) V1a &gt; /=7.5 % &lt; 11 % main group HbA1c &gt; /= 11.0 % additional parallel group 4 . Age &gt; /= 18 &lt; /= 80 year Visit 1a ( Screening ) 5 . Body Mass Index ( BMI ) &lt; / = 40 kg/m2 Visit 1a ( Screening ) 6 . Signed date write informed consent date Visit 1a accordance good clinical practice ( GCP ) local legislation Exclusion criterion : 1 . Uncontrolled hyperglycaemia require rescue medication placebo runin phase 2 . In main group , patient investigational medicinal product ( IMP ) compliance &lt; 80 % &gt; 120 % 2 week placebo run period 3 . Acute coronary syndrome stroke Transient ischaemic attack ( TIA ) within 3 month prior randomisation 4 . Impaired hepatic function , define serum level either Alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) , alkaline phosphatase ( AP ) 3 x upper limit normal ( ULN ) , total bilirubin 1.5 x ULN determine Visit 1a 5 . Known hypersensitivity allergy linagliptin excipients metformin placebo 6 . Treatment antiobesity drug 3 month prior inform consent treatment time screen 7 . Alcohol drug abuse within 3 month prior inform consent would interfere trial participation ongoing condition lead decrease compliance study procedure study drug intake opinion investigator . 8 . Concurrent participation another clinical trial investigational therapy within thirty day prior sign consent form trial . 9 . Premenopausal woman ( last menstruation &lt; /= 1 year prior informed consent ) nursing pregnant childbearing potential practicing acceptable method birth control , plan continue use method throughout study 10 . Current treatment systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent . 11 . Renal failure renal impairment Visit 1a ( screen ) Estimated Glomerular Filtration Rate ( eGFR ) &lt; 60 ml/min 12 . Bariatric surgery within past two year gastrointestinal surgery induce chronic malabsorption 13 . Dehydration clinical judgement investigator 14 . Clinical detect unstable acute congestive heart failure 15 . Acute chronic metabolic acidosis ( present patient history ) 16 . Hereditary galactose intolerance 17 . Known history pancreatitis chronic pancreatitis 18 . Medical history cancer ( except basal cell carcinoma ) and/or treatment cancer within last 5 year . 19 . Any clinical condition would jeopardize patient safety participate clinical trial discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>